Following nearly five decades with few approved therapies for acute myeloid leukemia (AML), the last three years have brought stellar progress with the U.S. Food and Drug Administration approving a nu
BT20 (TNBC) cells were cultured with either DMSO (v/v%) or Erlotinib (10uM) for 24 hours to observe differential expression changes between conditions. CAS-9 expressing BT20 (TNBC) cells were transduc
Raw counts of CRISPR/Cas9 activation screens using the Calabrese library upon regorafenib or DMSO treatment in GS-9, LN229, LN18, LNZ308, and T98G glioma cell lines
